Download App

Log in to access Online Inquiry
Company Overview More
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
CEO: Rodriguez, Raul R.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

RIGL Rigel Pharmaceuticals

2.120-0.020-0.93%
Close 05/19 20:00 ET
High
2.185
Open
2.130
Turnover
3.68M
Low
2.090
Pre Close
2.140
Volume
1.72M
Market Cap
364.75M
P/E(TTM)
Loss
52wk High
4.620
Shares
172.05M
P/E(Static)
Loss
52wk Low
1.800
Float Cap
364.07M
Bid/Ask %
0.00%
Historical High
114.750
Shs Float
171.73M
Volume Ratio
0.99
Historical Low
1.230
Dividend TTM
--
Div Yield TTM
--
P/B
53.00
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.00%
Amplitude
4.44%
Avg Price
2.140
Lot Size
1
Float Cap
364.07M
Bid/Ask %
0.00%
Historical High
114.750
Shs Float
171.73M
Volume Ratio
0.99
Historical Low
1.230
Dividend TTM
--
P/B
53.00
Dividend LFY
--
Turnover Ratio
1.00%
Amplitude
4.44%
Avg Price
2.140
Lot Size
1
Price Forecast

No Data

News

Comment